- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- Indian Pharma
Indian Pharma Stocks 
Here are the latest stock price details of India's top Indian Pharma stocks. For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AARTI DRUGS | 591.60 -0.50% | 589.85 -0.34% | More Info
|
|
| AJANTA PHARMA | 984.35 -0.57% | 984.25 -0.79% | More Info
|
|
| ALEMBIC PHARMA | 524.90 0.95% | 525.50 0.52% | More Info
|
|
| BIOCON LTD | 620.75 -0.14% | 621.20 -0.07% | More Info
|
|
| CADILA HEALTHCARE | 314.50 0.40% | 315.20 0.65% | More Info
|
|
| CIPLA | 541.75 -0.25% | 541.30 -0.77% | More Info
|
|
| DIVIS LABORATORIES | 1,565.05 0.98% | 1,565.00 0.97% | More Info
|
|
| GLENMARK PHARMA | 592.15 0.89% | 593.00 1.05% | More Info
|
|
| INDOCO REMEDIES | 173.50 -0.49% | 174.05 -0.17% | More Info
|
|
| IPCA LABS | 792.95 -0.99% | 792.85 -0.92% | More Info
|
|
| J.B.CHEMICALS | 328.90 3.22% | 329.65 2.94% | More Info
|
|
| LUPIN LTD | 776.85 0.88% | 777.70 1.03% | More Info
|
|
| NATCO PHARMA | 588.15 2.10% | 587.15 2.02% | More Info
|
|
| NIFTY 50 | Not Listed | 10,791.65 0.02% | More Info
|
|
| ORCHID PHARMA LTD | 3.37 4.66% | 18.90 -2.83% | More Info
|
|
| PANACEA BIOTECH | 178.35 7.50% | 178.60 8.21% | More Info
|
|
| PIRAMAL ENTERPRISES | 2,302.20 2.77% | 2,308.05 3.03% | More Info
|
|
| S&P BSE SENSEX | 35,871.48 -0.07% | Not Listed | More Info
|
|
| STRIDES PHARMA SCIENCE | 419.35 0.12% | 419.40 0.00% | More Info
|
|
| SUN PHARMA | 430.40 0.15% | 430.50 0.19% | More Info
|
|
| TORRENT PHARMA | 1,764.75 -0.18% | 1,765.50 -0.16% | More Info
|
|
| WOCKHARDT LTD. | 393.45 -1.13% | 393.70 -0.93% | More Info
|
BSE prices: February 22, 2019 (Close) NSE prices: February 22, 2019 (Close)
Indian Pharma Stocks Update
The NIFTY PHARMA Index was at 8,762.8 (up 0.7%). The index is down 15.0% over the last 30 days. And over the last 1 year, it has lost 6.7%.
Within the Indian Pharma sector, the top gainers were PANACEA BIOTECH (up 7.5%) and ORCHID PHARMA LTD (up 4.7%). On the other hand, WOCKHARDT LTD. (down 1.1%) and IPCA LABS (down 1.0%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 10,791.7 (up 0.0%).
|
| |
Today's Market
Recapitalisation Package for PSBs: The Pros & Cons(Podcast)
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
Related Views on News
PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)
Jan 1, 2019 | Updated on Jan 1, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Feb 12, 2019Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)
Feb 15, 2019Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More|
| |
S&P BSE HEALTHCARE
Feb 22, 2019 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.